BC­MA ri­val to blue­bird, Bris­tol My­ers files for $100M IPO as the fron­trun­ners stum­ble in a race to the fin­ish line

On the same day that blue­bird and Bris­tol My­ers had to try and ex­plain to an­a­lysts why their cru­cial ap­pli­ca­tion for the BC­MA drug ide-cel (bb2121) was kicked back by the FDA in a sting­ing refuse-to-file no­tice, a top con­tender for leapfrog­ging them to the mar­ket was lay­ing out a $100 mil­lion IPO and de­tails of the rich, $1.7 bil­lion deal with J&J that has been greas­ing the tracks of R&D and man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER